Clinical Trials Search
Clinical Trial 20562
Cancer Type: Cutaneous
Study Type: Treatment
NCT#: NCT04050436
Phase: Phase II
Prinicipal Investigator: Nikhil Khushalani
Study Title
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma
Summary
To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) according to central review.
Objective
The primary objective of this study is to estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), as assessed by overall response rate (ORR) according to central review. The secondary objectives of the study are: To estimate ORR for patients with locally advanced CSCC To estimate ORR for patients with metastatic CSCC To estimate ORR according to investigator review To estimate ORR for patients having previously received systemic CSCC-directed therapy To estimate ORR for patients not having previously received systemic CSCC-directed therapy To estimate the duration of response (DOR) by central and investigator review To estimate progression-free survival (PFS) by central and investigator review To estimate the complete response (CR) rate by central and investigator review To estimate overall survival (OS) To estimate the disease-specific survival (DSS) To estimate the 3 year survival To assess the safety and tolerability of cemiplimab alone and combined with RP1 To assess the change of cemiplimab and cemiplimab combined with RP1 on quality of life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30)
Therapies
Medications
Cemiplimab (); REGN2810 (Cemiplimab); RP1 ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.